Navigation Links
ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
Date:1/8/2009

at this first dose tested in the Phase Ib study," commented James Freddo, M.D., Anadys' Senior Vice President, Drug Development and Chief Medical Officer. "We believe this early data continues to position ANA598 as a leading non-nucleoside polymerase inhibitor in development for the treatment of HCV and we look forward to investigating ANA598 in longer-term studies in combination with current standard of care."

"The clinical and preclinical profile of ANA598 observed to date is very impressive," said Steve Worland, Ph.D., President and CEO of Anadys. "The magnitude of viral load drop reported today for ANA598 is greater than has been reported for any other non-nucleoside HCV inhibitor in a monotherapy study. Furthermore, the rate of initial viral load decline, believed to be associated with direct inhibition of viral replication, is greater than has been reported previously for all classes of HCV polymerase inhibitors, including nucleosides. This demonstrated antiviral potency holds significant promise for the future use of ANA598 in combination with other anti-HCV agents."

About ANA598

Anadys retains worldwide rights to ANA598, which was fully discovered at the Company. Preclinical evaluation of ANA598 was completed in the first quarter of 2008, leading to submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA), subsequent allowance of the IND by the FDA and initiation of clinical investigation in the second quarter of 2008. In December 2008, Anadys announced that the FDA granted fast track designation to ANA598 for the treatment of chronic HCV.

In October 2008, Anadys initiated patient dosing in the Phase Ib study of ANA598 in HCV patients. In the double-blind, randomized placebo-controlled Phase Ib study, treatment-naive genotype 1a and 1b patients are to receive oral capsules of ANA598 over three days at doses of 200 mg bid (twice
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
8. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
9. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
10. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Scott Steiger lives in St. Louis ... the past 20 years, he,s traveled extensively and prior to that, ... six of the seven continents. Travel is a big part of ... - http://photos.prnewswire.com/prnh/20141126/161077 So when he designs ... of what,s required. His latest creation is the Road ...
(Date:11/26/2014)... 2014 Zynerba Pharmaceuticals , Inc., a ... transdermal synthetic cannabinoid treatments, today announced that the company ... Conference 2014. The conference will be held December 2 ... New York . Zynerba,s Chairman and CEO, ... on Tuesday, December 2. To listen to ...
(Date:11/26/2014)... The medical magnetic resonance imaging (MRI) ... with world market revenues for 2013 at $5.1 ... types of medical imaging have led to improvements ... conditions in children and adults, each imaging procedure ... Medical Imaging Markets , analyzes the current and ...
Breaking Medicine Technology:Steiger Has Created the First Pill Case Specifically Designed For Travel 2Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3
... - New Data from Phase III Intergroupe Francophone ... Mass., July 02, 2007 /PRNewswire-FirstCall/ --,Millennium Pharmaceuticals, Inc. ... comparative Phase III clinical trial evaluating a,VELCADE based ... induction therapy prior to stem cell transplantation,(SCT), the ...
... 2 July, 2007 -- Ablynx today announced ... study of its lead,development programme, ALX-0081, an ... targeting von Willebrand Factor (vWF), which can,reduce ... acute coronary,syndrome. , The Phase I study ...
Cached Medicine Technology:Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 2Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 3Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 4Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 5Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 6Ablynx Announces Interim Results of First Nanobody Phase I Study of,ALX-0081 (ANTI-VWF) 2
(Date:11/28/2014)... Mabel’s Labels , the market leader ... award-winning company established by four moms, today announced that ... Mumby have been honored with a 2014 RBC Canadian ... Award for Excellence in Entrepreneurship. , All 4 partners ... accepted the award on behalf of Mabel’s Labels at ...
(Date:11/28/2014)... 2014 More than 2,100 Stryker ... filed in a New Jersey litigation that involves ... LLP reports. , A Case List updated ... reflects the filing of 2,160 claims over the ... were voluntarily recalled on July 6, 2012 by ...
(Date:11/28/2014)... 28, 2014 A newly released article ... overview of the influenza virus that will soon be spreading ... , The article begins with a brief explanation of what ... It reminds families that children under the age of 5, ... chronic diseases, such as heart and lung diseases, asthma, or ...
(Date:11/28/2014)... 28, 2014 UniWigs.com, a leader in the wig ... Friday to the next Monday. This promotion features: , ... 40 items up to 70% off (no coupon code needed), ... > Free shipping on orders over $49 , Visit http://www.uniwigs.com ... days from Nov. 28th to Dec. 1st and the first 100 ...
(Date:11/28/2014)... FL (PRWEB) November 28, 2014 Lice Troopers ... areas of its in-home head lice service for moms ... in the center of Coral Gables on Pone De-leon Blvd ... Bay Harbor Islands that service Miami-Dade & Broward. Lice ... salon in South Florida which has been treating families for ...
Breaking Medicine News(10 mins):Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 2Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 3Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 2Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 3Health News:How Flu Vaccines Can Impact Families Is Discussed in New Article from Community Health Center of Snohomish County 2Health News:Pre-X'mas Crazy Sale Starts from $0 at UniWigs.com 2Health News:Lice Troopers Lice Removal Service Expands in Miami-Dade 2
... improve oral health for youngsters ... ... companies of,Delta Dental of Michigan, Ohio, Illinois, Tennessee and Indiana are ... reduce the bacteria that causes tooth decay in nursing,home residents and ...
... Esteem Pass(TM) is Unique Electronically Processed Filtered Merchant Gift ... ... eCommLink, Inc., a leading provider,of secure, innovative prepaid debit programs, and ... and cards announced today the release of the Esteem Pass(TM).,Esteem Pass is ...
... in the United States will contract a sexually transmitted ... and Prevention. Experts believe a major contributing factor is ... and routinely. Now a new study provides some insight ... among teenagers. , Researchers from the Bradley ...
... Services® (PPS®), renowned for its award-winning healthcare websites, announces ... pediatric influenza, Preventing and Managing RSV Disease and Influenza ... , ... Secaucus, ...
... Inc., a traveling healthcare staffing company, is thrilled to ... of the fastest-growing private companies in the country. As ... No. 472 overall. When compared to other healthcare staffing ... was No. 1 for all traveling healthcare staffing companies. ...
... PRUSSIA, Pa., Sept. 8 Universal,Health Services, Inc. ... has signed a,definitive agreement to sell Central Montgomery ... in Lansdale, Pennsylvania to Abington Memorial,Hospital. The sale ... the closing to occur later this fall., ...
Cached Medicine News:Health News:How Many Licks Does it Take to Reduce Tooth Decay? 2Health News:How Many Licks Does it Take to Reduce Tooth Decay? 3Health News:How Many Licks Does it Take to Reduce Tooth Decay? 4Health News:Sodexo Releases Innovative Prepaid Incentive Card Powered by eCommLink 2Health News:Sodexo Releases Innovative Prepaid Incentive Card Powered by eCommLink 3Health News:Teens' failure to use condoms linked to partner disapproval, fear of less sexual pleasure 2Health News:PediatricRespiratory.org Announces a Two-Part, Live CME/CE Webcast Series on RSV and Pediatric Influenza 2Health News:PediatricRespiratory.org Announces a Two-Part, Live CME/CE Webcast Series on RSV and Pediatric Influenza 3Health News:PediatricRespiratory.org Announces a Two-Part, Live CME/CE Webcast Series on RSV and Pediatric Influenza 4Health News:Medical Solutions Ranks No. 472 in the 2008 Inc. 500 with Three-Year Sales Growth of 667.8% 2Health News:Medical Solutions Ranks No. 472 in the 2008 Inc. 500 with Three-Year Sales Growth of 667.8% 3Health News:Medical Solutions Ranks No. 472 in the 2008 Inc. 500 with Three-Year Sales Growth of 667.8% 4Health News:Universal Health Services, Inc. Announces Sale of Acute Care Hospital and Addition of Two Behavioral Health Hospitals 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 7.0 mm and length 8.7 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 9.0 mm and length 7.5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 10.0 mm and length 12 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 8.0 mm and length 9 mm....
Medicine Products: